Biocartis Goes Public on Euronext, Raising $128M

Apr 28, 2015

|

Update: The story was updated on May 19 to include information about the underwriters exercising their overallotment option, increasing the proceed amount raised from the offering.

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis went public on Monday in Belgium, raising about €115 million ($128 million) in proceeds.

The company issued 8,695,652 shares of its common stock at €11.50 per share as part of its initial public offering. Its shares list on Euronext Brussels under ticker symbol "BCART."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Bill to Address Foreign Influence

Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research.

Nobel Representation

In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.

Promising, But More Needed

Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.

Cell Studies Tackle Tissue Clones, Ocean Microbes, Polygenic Trait Prediction

In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.

Featured White Papers

Orthogonal Methods for Validation and Confirmation of Next-Generation Sequencing Results

Sample Normalization with RNAGEM

RNAGEM - mRNA Profiles as Close to Biological Reality as Possible

High-throughput Miniaturized Quantitative PCR with the Echo 525 Liquid Handler

Dec

17

Featured Webinar

Non-Invasive Characterization of Solid Tumors via NGS Liquid Biopsy Testing

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Jan

28

Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Menu

Biocartis Goes Public on Euronext, Raising $128M

To read the full story....

Breaking News

GenMark Diagnostics Downgraded by JP Morgan to Neutral

Twist Bioscience Fiscal Q4 Revenues Increase 87 Percent

Parkinson's Foundation Selects Five Sites for Genetic Testing, Counseling

Oxford BioDynamics Fiscal 2019 Revenues Down 24 Percent

At ASH, Researchers Discuss Rapid AML Nanopore Sequencing Assay for Analyzing Actionable Alterations

Enzo Biochem Fiscal Q1 Revenues Down 5 Percent

The Scan

Bill to Address Foreign Influence

Nobel Representation

Promising, But More Needed

Cell Studies Tackle Tissue Clones, Ocean Microbes, Polygenic Trait Prediction

Featured White Papers

Non-Invasive Characterization of Solid Tumors via NGS Liquid Biopsy Testing

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

What's Popular?

Bio-Rad Shares Dip Following Cyber Attack

NeuMoDx Molecular, Sentinel Diagnostics Partner for MDx Development

Hologic Vaginitis Tests Offer Improvements Over Gold Standard Methods

Co-Diagnostics Continues Global Expansion With Africa Alliance, New India Facility

Spartan Bioscience, Angiocare Ink Distribution Deal for CYP2C19 Test

Sponsorships